Impact of C.difficile infections on quality of life of patients


 

Clostridium difficile is the most common health care associated pathogen. Its consequences on the quality of life of patients lack generalized and robust data. The purpose of this study is to explore the consequences, if existing, of Clostridium difficile infections (CDI) on the quality of life of patients. These consequences may be physical, psychological, social, financial but also on their daily/work activities or on their chronic disease(s).

CDI is seen as an acute disease. This study will also explore the post-CDI symptoms that patients might experience after the acute infection and evaluate the length of these symptoms.

 

This study will help physicians, healthcare providers and policy makers understand the burden of CDI and to strengthen the need for therapies to combat and prevent CDI.

 

 

This survey is designed to evaluate what is important to you. Hence, it is self-adaptive to your experience. Answers can be as brief or as lengthy as you wish. You can simply check the boxes but we encourage you to use the narrative boxes to share your experience, observations and suggestions. However, participation is voluntary and you can stop participating at any time without having either to give any explanation or to worry about the successful continuation of the study.

 

Please, do not take this survey if you have not attained the legal adult age to consent (i.e. under 19 in the Alabama/Nebraska, under 21 in Puerto Rico and under 18 for any other State of the USA) and/or do/did not experience a Clostridium difficile infection.

 

Unless you explicitly give it to us, we do not collect identifiable information such as your computer IP address, contact information or location. Information collected in this study is used only for research purpose, all data will be aggregated and no individual response will be shared with any third party.

 

This survey has been determined to be exempt from Institutional Review Board review. It begins in August 2017 and will end after 342 participations.

 

Please contact the researchers in charge of the study (Dr. Thibaut Galvain - thibaut.galvain@cdiffsurvey.org and Dr. Lise Lurienne lise.lurienne@cdiffsurvey.org) if you have any questions.

 

 

 

 

 

 

A note on privacy
This survey is anonymous.
The record of your survey responses does not contain any identifying information about you, unless a specific survey question explicitly asked for it. If you used an identifying token to access this survey, please rest assured that this token will not be stored together with your responses. It is managed in a separate database and will only be updated to indicate whether you did (or did not) complete this survey. There is no way of matching identification tokens with survey responses.